Zenosense (OTC: ZENO)
Zenosense Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Zenosense Company Info
Zenosense, Inc. engages in developing medical devices for the diagnosis of heart attack and cardiac-related illnesses. It includes the detection of the Methicillin-resistant Staphylococcus aureus. The firm uses Acute Myocardial Infarction, and MIDS Cardiac technologies. The company was founded on August 11, 2008 and is headquartered in New Haven, CT.
News & Analysis
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.